Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19077884 | 0.89 | SMN1; SMN2 (0.36) | GRIN1GRIN2ASMN1; SMN2LTA4H | |
| SCHEMBL23338571 | 0.86 | GRIN1 (0.34) | GRIN1GRIN2ABRD4BRD2LTA4H | |
| SCHEMBL10168628 | 0.86 | GRIN1 (0.32) | GRIN1GRIN2ALTA4H | |
| SCHEMBL9963247 | 0.86 | LTA4H (0.37) | GRIN1GRIN2ABRD4BRD2LTA4H | |
| SCHEMBL16559763 | 0.83 | SMN1; SMN2 (0.39) | SMN1; SMN2 | |
| SCHEMBL16559762 | 0.81 | CYP2D6 (0.34) | SMN1; SMN2 | |
| SCHEMBL25959485 | 0.81 | GRIN1 (0.42) | GRIN1GRIN2ABRD4BRD2LTA4H | |
| SCHEMBL12832197 | 0.80 | CYP2D6 (0.33) | GRIN1GRIN2ASMN1; SMN2 | |
| SCHEMBL16190002 | 0.78 | GRIN1 (0.42) | GRIN1GRIN2ABRD4BRD2LTA4H | |
| SCHEMBL16559764 | 0.76 | CYP2D6 (0.39) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | GRIN1 3099/4885GRIN2A 2924/4885SMN1; SMN2 1139/4885 |
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | GRIN1 4755/4885GRIN2A 4793/4885SMN1; SMN2 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.